New bone drug LYN101 enters first human tests for osteoporosis
NCT ID NCT07178327
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug called LYN101 to see if it is safe and how the body processes it. First, healthy adults get a single dose. Then, postmenopausal women with low bone mass get multiple doses. The goal is to help control bone loss and prevent fractures, but this is not a cure—ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROTIC FRACTURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Sixth People's Hospital
Shanghai, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233060, China
Conditions
Explore the condition pages connected to this study.